Sukjoong Oh

1.3k total citations
52 papers, 783 citations indexed

About

Sukjoong Oh is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Sukjoong Oh has authored 52 papers receiving a total of 783 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 18 papers in Hematology and 16 papers in Genetics. Recurrent topics in Sukjoong Oh's work include Chronic Lymphocytic Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Lymphoma Diagnosis and Treatment (8 papers). Sukjoong Oh is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Lymphoma Diagnosis and Treatment (8 papers). Sukjoong Oh collaborates with scholars based in South Korea, United States and Thailand. Sukjoong Oh's co-authors include Seoung Wan Chae, Changick Kim, Cheolwon Suh, Dong‐Hoe Koo, Jong-Ho Won, Yun‐Gyoo Lee, Yeung‐Chul Mun, Hye Jin Kang, Chul Won Choi and Hyo Jung Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Sukjoong Oh

49 papers receiving 761 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sukjoong Oh South Korea	13	252	213	164	121	107	52	783
Roos J. Leguit Netherlands	19	214 0.8×	209 1.0×	113 0.7×	163 1.3×	158 1.5×	43	887
Tomás Álvaro Spain	20	618 2.5×	608 2.9×	134 0.8×	190 1.6×	165 1.5×	31	1.5k
Jacob R. Bledsoe United States	13	339 1.3×	177 0.8×	206 1.3×	129 1.1×	37 0.3×	47	731
Triantafyllia Κoletsa Greece	16	194 0.8×	131 0.6×	137 0.8×	172 1.4×	61 0.6×	104	844
Dong Soon Lee South Korea	17	267 1.1×	108 0.5×	58 0.4×	393 3.2×	153 1.4×	59	1.0k
Paulette Herlin France	17	400 1.6×	143 0.7×	102 0.6×	282 2.3×	71 0.7×	59	1.1k
Wanming Hu China	17	417 1.7×	82 0.4×	129 0.8×	215 1.8×	158 1.5×	78	944
U. Gunzer Germany	11	147 0.6×	97 0.5×	139 0.8×	61 0.5×	50 0.5×	25	607
H Helin Finland	17	203 0.8×	80 0.4×	170 1.0×	252 2.1×	48 0.4×	35	788
Eric J. Steenbergen Netherlands	12	122 0.5×	118 0.6×	52 0.3×	130 1.1×	78 0.7×	21	820

Countries citing papers authored by Sukjoong Oh

Since Specialization

Citations

This map shows the geographic impact of Sukjoong Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sukjoong Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sukjoong Oh more than expected).

Fields of papers citing papers by Sukjoong Oh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sukjoong Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sukjoong Oh. The network helps show where Sukjoong Oh may publish in the future.

Co-authorship network of co-authors of Sukjoong Oh

This figure shows the co-authorship network connecting the top 25 collaborators of Sukjoong Oh. A scholar is included among the top collaborators of Sukjoong Oh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sukjoong Oh. Sukjoong Oh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shin, Dong‐Yeop, Sa-Hee Park, Eun‐Jung Jang, et al.. (2024). Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials. Leukemia Research. 143. 107542–107542. 1 indexed citations

Song, Chang Myeon, et al.. (2024). Comparison of surgical outcomes of transoral robotic and endoscopic thyroidectomy: A systematic review and network meta‐analysis. Head & Neck. 46(3). 688–701. 5 indexed citations

Moon, Kyoung Min, Kyueng‐Whan Min, Woon Yong Jung, et al.. (2023). Low gamma‐butyrobetaine dioxygenase (BBOX1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma: a machine learning approach. The Journal of Pathology Clinical Research. 9(3). 236–248. 2 indexed citations

Lee, Sung‐Eun, Sung-Soo Yoon, Deok‐Hwan Yang, et al.. (2023). A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study. Blood. 142(Supplement 1). 4575–4575. 3 indexed citations

Lee, Yoo Jin, Yunsuk Choi, Misung Kim, et al.. (2022). Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma. Journal of Pathology and Translational Medicine. 56(5). 281–288. 2 indexed citations

Lee, Sung‐Eun, Soo-Young Choi, Soo-Hyun Kim, et al.. (2018). Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib. Leukemia Research. 70. 100–105. 4 indexed citations

Min, Kyueng‐Whan, Dong‐Hoon Kim, Byoung Kwan Son, et al.. (2018). High TNFRSF12A level associated with MMP-9 overexpression is linked to poor prognosis in breast cancer: Gene set enrichment analysis and validation in large-scale cohorts. PLoS ONE. 13(8). e0202113–e0202113. 28 indexed citations

Kim, Hawk, SooHyun Kim, Hyeoung‐Joon Kim, et al.. (2018). Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic–Phase Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 18(10). e391–e399. 12 indexed citations

Lee, Won-Sik, Hyeoung‐Joon Kim, Jee Hyun Kong, et al.. (2017). Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Blood. 130. 1593–1593. 1 indexed citations

10.

Min, Kyueng‐Whan, Dong‐Hoon Kim, Dong‐Hoon Kim, et al.. (2016). High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer. Postgraduate Medical Journal. 92(1094). 707–714. 8 indexed citations

11.

Min, Kyueng‐Whan, Seoung Wan Chae, Dong Hoon Kim, et al.. (2015). Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer. Oncology Letters. 10(1). 121–130. 27 indexed citations

12.

Lee, Yun‐Gyoo, Dong‐Hoe Koo, Sukjoong Oh, et al.. (2015). Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. Cancer Chemotherapy and Pharmacology. 76(5). 933–937. 4 indexed citations

13.

Min, Kyueng‐Whan, Dong Hoon Kim, Sung‐Im Do, et al.. (2015). Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 468(4). 409–416. 10 indexed citations

14.

Min, Kyueng‐Whan, Dong‐Hoon Kim, Sung‐Im Do, et al.. (2014). Expression patterns of stromal MMP-2 and tumoural MMP-2 and -9 are significant prognostic factors in invasive ductal carcinoma of the breast. Apmis. 122(12). 1196–1206. 37 indexed citations

15.

Kim, Hawk, Kyoo‐Hyung Lee, Inho Kim, et al.. (2014). Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: Fludarabine versus cyclophosphamide-ATG. Leukemia Research. 38(7). 730–736. 4 indexed citations

16.

Oh, Bae Jun, Sukjoong Oh, Sang‐Man Jin, et al.. (2013). Co-Transplantation of Bone Marrow-Derived Endothelial Progenitor Cells Improves Revascularization and Organization in Islet Grafts. American Journal of Transplantation. 13(6). 1429–1440. 42 indexed citations

17.

Choi, Soo-Young, Sung‐Eun Lee, Soo-Hyun Kim, et al.. (2012). Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study. Blood. 120(21). 3775–3775. 2 indexed citations

18.

Koo, Dong‐Hoe, Sang Hyuk Lee, Ki Bae Bang, et al.. (2012). Aggressive Classical Kaposi’s Sarcoma Mimicking Malignant Lymphoma. Pathology & Oncology Research. 18(4). 1067–1069. 1 indexed citations

19.

Goh, Hyun‐Gyung, Saengsuree Jootar, Hyeoung‐Joon Kim, et al.. (2011). Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study). Blood. 118(21). 2765–2765. 12 indexed citations

20.

Eom, Hyeon‐Seok, Yeo‐Kyeoung Kim, Joo-Seop Chung, et al.. (2009). Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Annals of Hematology. 89(5). 489–497. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact